OBI Pharma Inc (台灣浩鼎) yesterday released the results of its second and third-phase clinical trials of a new breast cancer drug, OBI-822, saying the outcome of the study shows “no statistical significance.”
While the study did not meet the primary efficacy endpoint of progression-free survival (PFS), the results still contain “meaningful scientific and clinical information,” which have provided “clear direction for future product development,” the company said in a statement.
OBI Pharma chairman Michael Chang (張念慈) said the company has received valuable information from the clinical trials, such as a substantial improvement in the PFS rate of the treatment group who demonstrated an immune response to the vaccine, as well as a clear, positive trend in the secondary endpoint of overall survival for patients.
Photo: CNA
“This information is very important for designing the global third-phase study of the new drug,” Chang said in the statement.
OBI-822 is designed to target Globo H, an oligosaccharide tumor antigen, to trigger the immune system to generate antibodies that activate cytotoxic T cells to destroy cancer cells.
Industry observers have viewed the drug as a promising aid to active immunotherapy for metastatic breast cancer, with curative effects far better than Herceptin of Swiss pharmaceuticals maker Roche Holding AG and Ibrance of US pharmaceuticals firm Pfizer Inc.
Chinese-language monthly Wealth Magazine executive director Hsieh Chin-ho (謝金河) yesterday raised some questions about OBI Pharma.
“The market was waiting for the results of OBI Pharma’s phase two and three trials for OBI-822 today, but the outcome is worse than expected, as it did not pass clinical trials,” Hsieh wrote in a post on his Facebook page. “How seriously will the news affect the company’s shares? I am afraid it cannot be taken in so easily,” he wrote.
OBI Pharma, the most expensive stock in the biotech sector, closed at NT$681 on the Taipei Exchange in Friday trading, down 3.81 percent from the previous session. The stock rose 3.97 percent this year and surged by 119.7 percent from its listing price of NT$310 in March last year.
The fate of the shares of another drug company in 2014 might be a lesson for OBI Pharma shares, Hsieh said, referring to Medigen Biotechnology Corp (基亞).
In July 2014, Medigen Biotechnology Corp announced an interim study of its new liver cancer drug, PI-88, saying it did not yield positive results, which drove its shares down for 20 straight sessions by the maximum daily limit until it fell to NT$112.5 from NT$459.
The sell-off in Medigen spread to other biotech stocks, causing great losses to investors at the time, Hsieh said.
Tesla Inc temporarily halted some production at its auto assembly plant in California because of problems with its supply chain, but work has begun to resume, CEO Elon Musk told employees in an e-mail on Thursday. “We are experiencing some parts supply issues, so took the opportunity to bring Fremont production down for a few days to do equipment upgrades and maintenance,” Musk said in an all-staff message seen by Bloomberg. The factory was “back up and running as of yesterday,” and would rapidly ramp up to full production of Model 3 and Model Y cars “over the next several days,”
Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) was on Thursday set to sell local currency bonds, as it prepared for a spending blitz amid a global chip shortage. The world’s largest contract chipmaker planned to price about NT$16 billion (US$565.25 million) of notes in three parts in an auction, though the actual issuance size might change. The manufacturer would have to contend with a recent rise in rates globally that has sent many corporate bond yields up from record lows in the past few weeks. The debt offering comes at a promising time for the semiconductor industry as the world scrambles its way
MULTI-USE: The arrangement of seats in future vehicles would be different, allowing passengers to do everything they do at home, the CEO of the firm’s EV platform said Electric vehicles (EVs) developed on a Hon Hai Precision Industry Co (鴻海精密) platform would be built like “a smartphone on a different platform,” Jack Cheng (鄭顯聰), chief executive officer of the Hon Hai-initiated MIH Open Platform Alliance, said on Saturday. It would be the ultimate goal to make vehicles built on the platform an extension of the driver’s home, he said during an online presentation. The alliance aims to provide resources to automakers and boost Taiwan’s EV development, with a vision to make an EV its owner’s “second home,” Cheng said. “Whatever they can do in their home, they will be able
‘MAINTAINING MOMENTUM’: The Swedish automaker might pursue plans for an initial public offering, which it had put on hold in 2018, the company said China’s Geely Automobile Holdings Ltd (吉利汽車) and its Swedish affiliate Volvo Cars are putting off earlier plans to merge, wagering that they would be more agile as standalone entities. The manufacturers would preserve their separate corporate structures, while cooperating more closely on electrification, autonomous-driving technology and software, a joint statement said. While they would no longer pursue a combination as announced last year, new listings could be on the table. “This is about maintaining top-line momentum,” Volvo chief executive officer Hakan Samuelsson said in an interview. “A merger isn’t always positive. You risk losing momentum because there’s too much internal focus.” Geely and
RSS